Life might have come from outer space, scientist say
Researchers have found complex organic molecules in a disc around a 'protostar' in a major breakthrough. Those molecules are seen as the precursors to the building blocks of life, which go on to become sugars and amino acids that are then combined into the complex flora and fauna that surrounds us.
Researchers have found such complex organic molecules in other places before. But the new findings fill in a previously mysterious missing link – one that could suggest that life is more abundant than we realise.
When cold protostar becomes a young star, surrounded by a disc of dust and gas, it is a violent process that includes intense radiation and the hurling out of gas. Researchers had been concerned that the extreme nature of that process could 'reset' the chemical compounds available around a star, meaning that they would have to be formed in the discs that at the same time are making planets.
But the new findings suggest that complex molecules can stick around through that process, meaning they will be inherited by the discs that follow.
The findings are reported in a new study, 'A deep search for Complex Organic Molecules toward the protoplanetary disk of V883 Ori', published in the The Astrophysical Journal Letters.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
5 hours ago
- Daily Mail
Scientists discover remarkable health impact of a daily 'fast walk'
Hitting 10,000 steps a day is a goal for millions of us—but we should be focusing on the pace not the paces, according to a new study. Research suggests that going on a daily brisk 15-minute walk could boost heart health and reduce risk of death by 19 per cent. US researchers, who studied more than 79,850 adults from low-income areas, found that a short brisk walk was more beneficial than walking at a slower pace for three hours, even when overall leisure-time physical activity levels were accounted for. Experts argued that the findings show that walking, particularly at a brisk pace, is an effective form of exercise—especially for those in low income areas— that could protect against heart disease. It comes as alarming data released last year revealed that premature deaths from cardiovascular problems, such as heart attacks and strokes, had hit their highest level in more than a decade. In the UK, around 420 people of working age die of as a result of heart disease each week, which works out as 21,975 people a year. In the current study, which analysed data from the Southern Community Cohort Study between 2002 and 2009, participants reported how many minutes they spent per day engaging in walking slowly and walking fast. Walking at work, engaging in light exercise or walking the dog were classed as 'walking slowly', whereas more dynamic activities such as climbing the stairs, brisk walking and exercise were considered fast. Over a follow-up of just under 17 years, the researchers discovered that walking fast for as little as 15 minutes per day reduced the risk of all cause mortality by nearly 20 per cent. Writing in the American Journal of Preventive Medicine, they found the effect was most pronounced for cardiovascular disease. According to Professor Wei Zeng, lead investigator and expert in lifestyle factors and diseases, fast walking could reduce cardiovascular mortality by improving how efficiently the heart works and reducing obesity. This style of exercise has previously been shown to increase VO2-max —a measure of how much oxygen the body can process during exercise. A high VO2 max is associated with better physical fitness and lower risk of cardiovascular disease, indicating that the body is efficiently extracting and using oxygen from the blood. Prof Zeng concluded: 'Brisk walking offers a convenient, accessible and low-impact activity that individuals of all ages and fitness levels can use to improve general health and cardiovascular health specifically.' The experts, lead by Professor Lili Liu, lead author and trainee epidemiologist, are now urging health officials to encourage fast walking within all communities—especially those with limited access to healthcare—and address barriers to daily walking such as safety concerns. They added: 'Public health campaigns and community-based programmes can emphasise the importance and availability of fast walking to improve health outcomes. NHS data shows a rise in the number of younger adults suffering from heart attacks over the past decade. The biggest increase (95 per cent) was recorded in the 25-29 year-old demographic, though as numbers of patients are low even small spikes can look dramatic 'Individuals should strive to incorporate more intense physical activity into their routines, such as brisk walking or other forms of aerobic exercise.' The scientists, however, acknowledged that because physical activity data was only collected at the beginning of the study, changes in activity levels could not be considered. The paper also had some limitations, they said, including the fact daily walking levels were self-reported. Sedentary lifestyles in the UK, with Brits spending their workhours deskbound, then sitting in a train or car on their way home to sit down in front of the TV, have been estimated to kill thousands each year. The WHO puts the annual global death toll from physical inactivity at around 2million per year, making it in the running to be among the top 10 leading causes of global death and disability. Physical inactivity has been long linked to health problems like cardiovascular disease as well contributing to health problems like obesity, itself linked to an increased risk of type 2 diabetes and some cancers. Cases of heart attacks, heart failure and strokes among the under-75s had tumbled since the 1960s thanks to plummeting smoking rates, advanced surgical techniques and breakthroughs such as stents and statins. But now, other factors such as slow ambulance response times for category 2 calls in England — which includes suspected heart attacks and strokes — as well as long waits for tests and treatment have also been blamed.
The Independent
6 hours ago
- The Independent
Simple diet change could improve your cholesterol levels, research finds
Research from King's College London indicates that consuming a diverse range of 11 different plant-based foods daily is associated with improved health. The study found that a varied plant diet, including fruits, vegetables, pulses, herbs, spices, and oils, led to better cholesterol levels, blood sugar markers, and overall diet quality. Current UK dietary guidance often emphasises quantity, such as 'five-a-day', but the findings suggest that variety across all plant food groups is equally crucial for health. Participants with higher plant diversity in their diets also exhibited healthier lifestyles, including lower smoking rates, compared to those with less diverse diets. Experts advise incorporating a wider array of plant foods like legumes, nuts, seeds, herbs, and spices to enhance dietary diversity beyond just fruits and vegetables.
The Sun
7 hours ago
- The Sun
‘Game-changing' Alzheimer's drug could STOP disease in its tracks – as the ‘most powerful weapon' against condition yet
A NEW "game-changing" drug could stop the progression of Alzheimer's disease, early trials suggest. Scientists say the treatment - called trontinemab - could be the most powerful weapon yet against dementia, as they look into giving the drug to people with no symptoms in the hopes of preventing disease. 1 Phase two trial results for trontinemab were presented at he Alzheimer's Association International Conference in Toronto. Researchers said the drug seemed to clear plaques - the abnormal build-up of proteins around brain cells that cause damage and disrupt function - quicker than other drugs licensed to treat Alzheimer's. Trontinemab cleared out plaques and eliminated visible signs of the the disease within 28 weeks for nine out of 10 patients. Drug-maker Roche is now conducting another trial to see if plaque clearance also improves patients' memory. The 18-month study includes 1,600 people, the Telegraph reported. Separate research will examine whether the drug could be given to people without any signs of dementia, just as statins are used to ward off heart disease. Experts hope the drug could stop patients from developing dementia symptoms at all, if it is given early enough. They described the findings so far as 'very promising', suggesting that the drug was much more powerful than existing ones while leading to fewer side effects - as it was able to clear plaques better within seven months that other drugs can in 18 months. Roche's chief medical officer Levi Garraway said: 'Alzheimer's disease represents one of the greatest challenges in healthcare today and tackling it requires early detection and effective therapeutics. 'Trontinemab is designed to target a key driver of Alzheimer's disease biology more effectively in the brain. "Combining new treatment avenues with advanced diagnostics may enable earlier and potentially more effective intervention. "With plans for phase three trials in both early symptomatic and pre-clinical Alzheimer's disease, we are advancing science with the goal of delaying - and ultimately preventing - progression of this devastating condition.' Prof Sir John Hardy, the chairman of molecular biology of neurological disease at University College London's Institute of Neurology told the Telegraph trontinemab could be 'game-changing'. The scientist, who was the first to identify the role of amyloid plaques in Alzeheimer's, said: 'This is absolutely great news. "It sucks the plaque out of the brain really quickly, much faster than we have seen with lecanemab or donanemab.' Both are Alzheimer's drugs approved for used in the UK, which target amyloid proteins in the brain to slow disease progression. However, neither treatment is offered on the NHS, as the National Institute for Health and Care Excellence (Nice) deemed them too expensive - in large part because patients need frequent scans to monitor for brain swelling and bleeds. Prof Hardy added: 'There is no doubt [trontinemab] could be game-changing. "We hope that if we can use these drugs to people early, we can halt the progression of disease, even before people have symptoms. "Now we need to see the size of the clinical effect. 'These results show it is much faster and safer than previous drugs, which means less monitoring. "That brings down the cost significantly, it means fewer MRI scans, so that would surely mean it would get Nice approval.' Early signs of dementia It's not unusual for your memory to lapse a bit as you get older. But dementia is different from 'just getting old' as it will cause noticeable - rather than gradual - changes to mental abilities and make managing everyday tasks and activities increasingly difficult. The symptoms of dementia may be small to start with, but get worse over time. Below are some examples of possible signs. Memory loss Memory loss is a key sign of dementia. This can include: Forgetting something you were only recently told. You may ask for the same information repeatedly – for example, 'Are the doors locked?' Putting objects in unusual places – for example, putting your house keys in the refrigerator. Being unable to learn new tasks, like how to use a new washing machine. Planning and decision making issues People with dementia can have difficulty with planning and decision making. This can include: Getting very confused when planning or thinking things through. Struggling to stay focused on a single task. Not making informed, careful decisions when dealing with money or looking at risks. Finding it hard to manage regular payments, budgets or monthly bills. Problems with language and understanding In people with dementia, this can manifest as: Having frequent problems finding the right word or regularly referring to objects as 'that thing'. Finding it hard to take part in conversations. Regularly being unable to follow what someone is saying even without distractions. Losing sense of time and place Dementia can cause problems with orientation, including: Losing track of the date, season or the passage of time. Getting lost in a place that is familiar or that should be easy to find your way around – for example, a supermarket. Regularly being unable to follow what someone is saying even without distractions. Problems with vision and perception This can mean having problems making sense of what you see. For example, having difficulty judging distances on stairs, or mistaking reflections or patterns for other objects. Mood and behavioural changes Finally, dementia can also make people act differently or shift their mood. This can mean: Becoming withdrawn and losing interest in work, friends or hobbies. Feeling unusually sad, anxious, frightened or low in confidence. Getting easily upset at home, at work, with friends or in places that usually feel comfortable or familiar. Trials for lecanemab and donanemab showed the drugs helped clear toxic clumps out of the brain and slow nerve damage caused by Alzheimer's by 27 per cent and 35 per cent respectively, over the course of 18 months. But the treatments did present a risk of brain swelling and brain bleeds, meaning patients needed intense monitoring. Trontinemab appears to be safer and cause fewer side effects, with less than five per cent of patients showing abnormal results on their brain scans. All of these cases were quickly resolved, researchers said. The drug - administered by infusion into the bloodstream - also doesn't need to be given a frequently. Upcoming trials will examine the impact of giving the drug to patients once a month for six months, then every three months. Trontinemab has been designed to efficiently bypass the blood-brain barrier, a protective layer of cells that stops harmful substances in the blood stream from attacking the brain and spinal cord. This barrier can make it hard for many drugs to reach the brain. Prof Jonathan Schott, the chief medical officer at Alzheimer's Research UK, told the Telegraph: 'We urgently need a range of treatments for Alzheimer's that are effective and safe for the people affected by this devastating disease. 'Evidence presented at the Alzheimer's Association conference in Toronto on trontinemab is very promising, showing that the drug can effectively and rapidly clear amyloid from the brain, seemingly with very few side effects. 'We now need to see whether these early stage results carry through to later stage clinical trials, which are planned to start later this year, including in the UK. "These trials will show whether the drug is not only safe, but impacts on memory, thinking and quality of life.' He said it was 'exciting' that the drug would now be tested in some people without symptoms under the phase three trials.
